Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

Lerner Receives FDA Clearance For Levia

For personal targeted phototherapy treatment of Psoriasis

Lerner Medical Devices (Lerner) has reported that Levia, an in-home, ultraviolet B (UVB) phototherapy device, has received 510 (k) clearance from the FDA for treatment of psoriasis and certain other skin conditions such as vitiligo. Levia enables patients to treat privately their chronic scalp and small area psoriasis with a safe and effective non-drug option, personal targeted phototherapy.

Levia is purpose-designed to facilitate personal treatment of scalp and small area psoriasis flare-ups in the home environment, with physician control and oversight. Levia’s proprietary touch-screen user interface permits the patient to manage the delivery of a physician-prescribed treatment regimen with appropriate flexibility.

The company said that Levia’s proprietary beam delivery attachments, Lite-Brush and Lite-Spot, direct UVB light to the affected areas of scalp and skin. This precise targeting minimizes exposure of uninvolved areas and ensures controlled and rapid treatment.

John Lyon, CEO of Lerner, said: “UVB phototherapy is a proven, non-systemic treatment for psoriasis which is under-utilized, because, as a cumulative therapy, it requires multiple office visits, with attendant multiple co-pays. Levia and Personal Targeted Phototherapy now offer psoriasis patients and their physicians the ability to utilize the non-drug option of UVB light in a private home environment, with a highly efficient treatment regimen and built-in safeguards.

“We believe that Personal Targeted Phototherapy with Levia represents a new standard of therapeutic effectiveness, convenience and control in the treatment of psoriasis. We expect Levia to be available to patients in the first quarter of 2010.”